Jefferies Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $26
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Jefferies analyst Akash Tewari initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $26.
Jefferies analyst Akash Tewari initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $26.